Welcome to our dedicated page for Greenwich LifeSciences news (Ticker: GLSI), a resource for investors and traders seeking the latest updates and insights on Greenwich LifeSciences stock.
Greenwich LifeSciences, Inc. reports developments as a clinical-stage biopharmaceutical company focused on FLAMINGO-01, a Phase III clinical trial evaluating GLSI-100 as an immunotherapy intended to prevent breast cancer recurrences. GLSI-100 combines the GP2 peptide with GM-CSF and is described by the company as a Fast Track designated program.
Recurring news includes FLAMINGO-01 clinical-site activity, oncology conference abstracts and posters, open-label immune-response and recurrence-rate data, patent-claim updates tied to GP2, at-the-market equity financing activity, and SEC reporting or Nasdaq compliance matters related to periodic filings.
Greenwich LifeSciences (Nasdaq: GLSI), a clinical-stage biopharmaceutical company, announced it will rejoin the Russell 2000 and Russell 3000 Indexes. This reconstitution will take effect on July 1, 2024. GLSI is focused on its Phase III clinical trial, FLAMINGO-01, which evaluates GLSI-100, an immunotherapy for preventing breast cancer recurrences. CEO Snehal Patel noted that the inclusion in the Russell 2000 Index is anticipated to increase institutional ownership, reflecting the company's progress in expanding FLAMINGO-01 into Europe and up to 150 clinical sites globally.
Greenwich LifeSciences (Nasdaq: GLSI) announced a private placement agreement with CEO Snehal Patel. The agreement involves the sale of 174,825 shares at $14.30 per share, totaling approximately $2.5 million. The closing is anticipated around June 18, 2024, subject to customary conditions. The proceeds will be used for clinical development and working capital. No investment banking fees are involved, and Patel has agreed to a one-year lock-up period for the acquired shares. The transaction was conducted under Section 4(a)(2) of the Securities Act of 1933 and Regulation D, meaning the shares are not registered and can only be resold under certain conditions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Greenwich LifeSciences (NASDAQ: GLSI) provided a year-end update on its clinical-stage immunotherapy, GLSI-100, aimed at preventing breast cancer recurrences. The company is expanding the Flamingo-01 Phase III trial, currently involving 20 US clinical sites recruiting patients, with plans to add 60-75 sites in Europe. CEO Snehal Patel expressed optimism from meetings at the 2022 SABCS and announced commercial manufacturing efforts for GP2, aiming to produce approximately 200,000 doses. A new patent application was filed regarding GP2’s use in immune response assays, enhancing the company's intellectual property portfolio.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) has announced an extension to the lock-up period for shares owned by directors, officers, and pre-IPO investors until December 31, 2023, approximately 39 months post-IPO. The company is focused on developing GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences in patients post-surgery. The ongoing Phase III clinical trial, Flamingo-01, will evaluate the safety and efficacy of GLSI-100 in HER2/neu positive breast cancer patients. The trial aims to detect a hazard ratio of 0.3 in invasive breast cancer-free survival.